Acting FDA Commissioner Lester Crawford said the same cardiovascular risk that was found in Merck's Vioxx may not be present in other pain relievers in the same COX-2 class of drugs. Crawford said the agency believes drugs within that class "are as diverse as the statin drugs," a statement similar to one made earlier this week by another official who said there was no definitive evidence others in the drug class, such as Celebrex, Bextra and Arcoxia, carry the same heart risk as Vioxx, pulled from the market three weeks ago.

Full Story:

Related Summaries